Red flags when evaluating a peptide supplier

Before anything else: is a certificate of analysis published per lot, and is it available before you buy rather than promised after? A supplier who cannot show documentation for material they are currently selling is not going to produce better documentation once payment has cleared.

What the certificate should actually contain — identity, purity, net peptide content, and named contamination screens — is covered in full on the certificate-of-analysis page. This section assumes the document exists and moves to signals that sit outside it.

Real measurements vary. A purity figure that reads identically across different lots of the same compound is worth a second look, and a set of figures that reads identically across entirely different compounds is a stronger signal still.

When the same purity percentage, the same panel list, and the same descriptive language appear verbatim across a whole catalog — a growth-factor peptide and an unrelated mitochondrial peptide carrying word-for-word specifications — that is evidence the numbers were written into a template rather than measured on each material. Synthesis and testing produce some variation between batches almost by definition. Uniform, repeated figures across unrelated products suggest the figures were never the output of a test.

A result is only as trustworthy as its independence from the party being graded. A supplier reporting its own in-house purity figure has an obvious incentive that a named, contactable third-party laboratory does not.

This is checkable directly: does the certificate name the laboratory, and can that laboratory be found independently of the supplier's own site? A figure attributed to "our lab" is answering a different question than one attributed to a laboratory a buyer could contact directly.

A price well below the rest of the category is not automatically evidence of anything — efficient operations exist. But every input into a properly analyzed peptide has a real cost floor: synthesis, purification, and the testing panel itself all cost money that shows up somewhere.

When a price sits at a fraction of the category average for an equivalent specification, the honest question is what was cut to get there. Testing is usually the first candidate, because it is the one input a buyer cannot see the absence of without asking.

A named legal entity, a real postal address, and a contact method that reaches an actual person are basic transparency, not a courtesy. It is not that a research buyer typically needs to visit — it is that a business willing to be found is a business that expects to still be answering questions next year.

A storefront with no company name behind it, or a contact form as the only way to reach anyone, is a business that has made itself hard to hold to anything it says today.

The research-use designation and everything it implies is covered in full on its own page, including the consistency test worth running on any supplier's site: do the label, the product copy, and any published articles all describe the same scope in the same terms? Divergence between them is usually the most reliable single tell, because it is harder to fake consistently than any individual document.